Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer

No evidence is available on the head-to-head comparison of clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) in a real-world setting. We aimed to compare the effectiveness and cost-effectiveness profile of nivolumab, pembro...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Matteo Franchi, Giacomo Pellegrini, Giovanni Corrao
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2022-04-01
Schriftenreihe:	Pharmaceuticals
Schlagworte:	non-small cell lung cancer immune checkpoint inhibitors real-world effectiveness cost-effectiveness
Online-Zugang:	https://www.mdpi.com/1424-8247/15/4/489
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!